| Dr David Mathis Thayn, | |
|
300 N Hospital Dr, Price, UT 84501-4218 | |
| (435) 637-4800 | |
| (435) 637-9513 |
| Full Name | Dr David Mathis Thayn |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 18 Years |
| Location | 300 N Hospital Dr, Price, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386802916 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 5245798-1205 (Utah) | Secondary |
| 208M00000X | Hospitalist | 5245798-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Castleview Hospital | Price, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Castleview Physician Practice, Llc | 6305995598 | 18 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Castleview Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639253321 PECOS PAC ID: 9032021043 Enrollment ID: O20040105000319 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Uintah Basin Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871556217 PECOS PAC ID: 0244131944 Enrollment ID: O20040226000948 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Northeastern Utah Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982664199 PECOS PAC ID: 2961496609 Enrollment ID: O20040414000471 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Ashley Valley Physician Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740482025 PECOS PAC ID: 4284683947 Enrollment ID: O20050119001166 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Castleview Physician Practice, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013364884 PECOS PAC ID: 6305995598 Enrollment ID: O20090518000607 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Entity Name | Western Medical Consultants |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790175073 PECOS PAC ID: 0446577290 Enrollment ID: O20150316002507 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Mathis Thayn, 300 N Hospital Dr, Price, UT 84501-4218 Ph: (435) 637-4800 | Dr David Mathis Thayn, 300 N Hospital Dr, Price, UT 84501-4218 Ph: (435) 637-4800 |
News Archive
A successful, and novel, technique to kill metastatic breast cancer cells by circumventing their chemo- and radioresistant mechanisms was by presented by Dr John Giannios, Head of Radiotherapeutic Cancer Research at the IASO Hospital
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.
Royal Sussex County Hospital, part of Brighton and Sussex University Hospitals has helped to reduce the administration of general anaesthetic by a third in patients aged 4-17 by expanding its MR capability with the help of new technology from Siemens Healthcare.
Low-density lipoprotein cholesterol levels should be lowered as much as possible to prevent cardiovascular disease, especially in high and very high risk patients.
ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.
› Verified 4 days ago